- Raised $500k funding round led by NGT3
About
Synnerva is a privately held, early-stage pharmaceutical company focused on the development and commercialization of proprietary central nervous system (CNS) drug compositions allowing significant reduction of the effective doses and elimination of side effects. The company has developed a new technological platform for the concurrent increase of CNS drug efficacy while dramatically reducing their side effects. Synnerva's method is based on a combination of generic, FDA-approved APIs with stimulators of vagal afferents. Its proprietary compositions of CNS drugs (levodopa for Parkinson's disease, morphine, amitriptyline for pain, valproate for epilepsy, etc) in low or sub-therapeutic doses with sub-therapeutic doses of glutamate antagonists and/or adrenomimetics lead to unusual synergistic enhancement of the therapeutic effects of CNS drugs that is not accompanied by side effects. The company's concept has been proven in animal models validated for appropriate clinical indications. The company's portfolio of drugs improved by its compositions in vivo include levodopa, morphine, amphetamine, mematine, sodium valproate, and amitriptyline.
Funding history · 1 round · $500K total
Q&A
- What is Synnerva's current operational status?
- Synnerva is currently inactive, having ceased operations in March 2024.
- What is Synnerva's primary focus?
- Synnerva is an early-stage pharmaceutical company focused on developing and commercializing proprietary central nervous system (CNS) drug compositions that reduce effective doses and eliminate side effects.
- What is the core technology behind Synnerva's drug compositions?
- Synnerva's method combines generic, FDA-approved APIs with stimulators of vagal afferents to enhance CNS drug efficacy while reducing side effects. This has been proven in animal models for various clinical indications.
- Which therapeutic areas does Synnerva's drug portfolio address?
- Synnerva's drug compositions have shown improvement in treatments for Parkinson's disease (levodopa), pain (morphine, amitriptyline), and epilepsy (valproate), among others.
- How much funding has Synnerva raised in total?
- Synnerva has raised a total of $500,000.
- When was Synnerva founded?
- Synnerva was founded in July 2019.
Team · 1
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
Identifiers & details
| Founded | 2019-7 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Mar 2024 ceased to operate |